<p>, /PRNewswire/ -- 随着减肥药市场竞争的逐渐加剧，博瑞医药（688166.SH）最新披露的 BGM0504 三期临床数据重新点燃了市场的关注。</p>
<p>在高血压人群中，平均体重减少 19.3%，腰围减少 16.5 厘米，收缩压降低 22.9 mmHg，尿酸降低 70.7 μmol/L，甘油三酯降低 33.6%，尽管体重下降，骨密度却显示出改善而非下降，高剂量组的停药率为 0.7%。如果这些指标单独出现，其重要性主要反映在疗效提升上；然而，当多个参数在单一产品中同时实现时，这类疗法的作用从单一的体重管理扩展到全面的代谢管理。</p>
<p>在这种背景下，之前被视为辅助角色的目标现在进入了核心聚光灯：GIP。</p>
<p>在过去十多年中，GLP-1 定义了减肥药的商业模式——以体重减少为核心终点的高价值创新疗法。随着双激动剂时代的推进，GIP 的角色正在发生转变，从最初主要贡献于耐受性调节的认知，演变为代谢结构调节中的关键变量。这一转变的重要性不仅在于增加了另一个靶点，更在于与 GIP 激活相关的更广泛的代谢效应。</p>
<p><strong>从单一终点到多参数协同</strong></p>
<p>从创新轨迹的角度来看，体重管理领域已经经历了明显的升级周期。</p>
<p>单靶点的 GLP-1 药物，其核心价值主要体现在体重减轻和血糖控制上，而对血压、脂质和其他参数的影响大多是次要的、伴随的改善。随后，双激动剂将体重减轻幅度推向接近 20% 的范围，并在某些代谢标志物上扩展了益处，但整体市场定价仍然以体重减少和降低血糖作为主要终点。</p>
<p>在这种背景下，BGM0504 的独特之处并不是在任何单一指标上的突破，而是多个终点的协调改善。</p>
<p>腰围减少 16.5 厘米表明对内脏脂肪的直接影响——这是核心风险驱动因素——而不是仅限于体重的影响。收缩压降低超过 20 mmHg，且目标达成率超过 90%，使得效果从 “附带改善” 转变为临床可操作的范围。尿酸降低 70.7 μmol/L 和甘油三酯降低超过 30% 接近专门代谢疗法通常见到的幅度。</p>
<p>更重要的是，在接近 20% 的体重减轻背景下，骨密度没有下降而是增加，同时停药率保持在低水平的 0.7%。这表明，改善的疗效并不是以骨质流失或治疗依从性降低为代价实现的。</p>
<p>当一款药物能够同时改善体重、血压、血脂和尿酸时，它在多个慢性病人群中展现了效果。</p>
<p><strong>从机制到差异化：GIP 的崭露头角</strong></p>
<p>如果 BGM0504 的三期临床数据代表了结果，那么机制决定了这些结果是否可以解释和持续。</p>
<p>在 GLP-1 通路中，体重减轻主要源于摄入控制，通过抑制食欲和延迟胃排空来实现。血压、脂质谱和其他标志物的改善在很大程度上是体重减少的次要结果。</p>
<p>相比之下，GIP 更像是代谢系统内的内在调节变量。GIP 受体在脂肪组织中高度表达。激活后，它调节脂肪组织的血流和炎症状态，从而调节脂肪分布。这个过程不仅影响体脂百分比，还通过增强胰岛素敏感性推动多个参数的协调改善，包括血脂和血压。</p>
<p>从 BGM0504 的三期数据中，可以清晰地观察到与这一机制通路的相关性。腰围减少 16.5 厘米表明对内脏脂肪的影响，这是一个关键的心代谢风险因素。甘油三酯减少 33.6%，伴随 LDL-C 降低和 HDL-C 升高，显示出脂质代谢的有利重塑。尿酸降低 70.7 μmol/L 可以视为优化代谢环境的协调结果。</p>
<p>在血压方面，多种因素协同作用——包括减少脂肪炎症、改善胰岛素抵抗和增强血管内皮功能——导致收缩压降低超过 22.9 mmHg，合并高血压患者的控制率达到 92.9%。这一特征反映了整体的、代谢驱动的调节效应。</p>
<p>在脂质代谢水平上，GIP 改善胰岛素敏感性并调节脂蛋白代谢，从而影响极低密度脂蛋白（VLDL）的肝脏合成和分泌，同时促进外周组织的甘油三酯清除。这导致甘油三酯减少 33.6% 和脂蛋白组成优化。尿酸代谢的变化在很大程度上反映了代谢级联效应。在肥胖和胰岛素抵抗中，肾脏尿酸排泄受损。通过改善胰岛素敏感性、减少脂肪炎症和优化能量代谢，GIP 有助于恢复尿酸排泄的平衡。</p>
<p>骨代谢是 GIP 机制的一个独特特征，得到了确凿的人类和机制证据的支持。例如，发表在《临床内分泌与代谢杂志》上的一项研究表明，GIP 显著抑制骨吸收，与胰岛素无关。GIP 受体在成骨细胞中表达；其激活通过调节 RANKL/OPG 通路促进骨形成并抑制骨吸收，从而有助于骨重塑。此外，当与 GLP-1 结合时，GIP 还会产生附加效应。多项综述已将 GIP 确定为肠 - 骨轴中的关键调节激素，介导餐后骨重塑期间的骨吸收抑制和骨形成调节。</p>
<p>在传统的单靶 GLP-1 通路中，快速减重通常伴随着骨矿密度的下降，研究表明，增加 GIP 可以抵消这一风险。因此，尽管体重显著减少，但骨矿密度没有下降，甚至出现改善趋势，可以通过减少骨吸收、增强骨形成和优化代谢环境的组合来机制性解释。这也为慢性疾病管理中双靶治疗的长期结构稳定性提供了机制支持。</p>
<p>总体而言，GIP 不仅仅是一个增强减重的辅助靶点。相反，它参与了多个维度的系统级调节，包括脂肪分布、代谢交叉对话和组织稳态的维持。当这一通路有效激活时，治疗的影响不再局限于体重这一单一终点，而是扩展到更广泛的代谢参数。这一转变也为理解 BGM0504 在多个心脏代谢指标上同时改善提供了机制基础。</p>
<p>BGM0504 的独特之处在于它在设计阶段故意增加了 GIP 的权重。根据《自然 - 科学报告》的一项出版物，其双激动剂活性约为 tirzepatide 的三倍。这一差异不仅仅是 “更强的效力”；相反，在可比剂量水平下，BGM0504 似乎实现了更高的 GIP 受体结合和更有效的信号激活，实质性地增加了 GIP 对整体药理学的贡献。</p>
<p>在这一架构中，GLP-1 和 GIP 承担着不同的角色：GLP-1 提供减重和血糖控制的基础效应，而 GIP 则更多地贡献于脂肪分布调节、代谢交叉对话和耐受性优化。</p>
<p><strong>从产品到平台：GIP 准备推动新一波差异化</strong></p>
<p>一旦差异化从机制扩展到商业模式，类别层面的变化便开始显现。在全球范围内，体重管理领域正从单靶向方法转向多靶向组合，同时扩展到多种制剂和给药途径。除了 GLP-1 和 GIP，口服选择、淀粉酶、肌肉保护靶点和脂肪信号通路都成为了活跃的探索前沿。</p>
<p>在这一背景下，博瑞医药的战略更接近于平台型方法。</p>
<p>围绕 BGM0504，公司不仅加强了其机制中的 GIP 成分，还推进了多个平行项目和模式，包括 BGM0504 与淀粉酶、MSTN 环肽、ALK7 靶向 siRNA 以及几种口服制剂的组合。目标是组建一个涵盖脂肪组织、肌肉、骨代谢和多种给药场景的系统能力。换句话说，论点不再仅仅是开发一种减重药物，而是构建一个更广泛的代谢调节平台。</p>
<p>这让我们回到最初的问题：为什么 BGM0504 能够在多个终点上同时实现一致的改善？GIP 影响多个代谢通路。临床试验表明，GLP-1/GIP 双激动剂在体重、血糖控制、血压、脂质代谢和尿酸水平等方面产生效果。GIP 正日益成为塑造这一领域下一阶段差异化的关键变量。</p>
<p>来源：博瑞医药</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041NTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwMjA4UFJfTkVXU19VU1BSX19fX19DTjU1ODAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041NTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwMjA4UFJfTkVXU19VU1BSX19fX19DTjU1ODAy"/></p>

博瑞医药

<p>博瑞医药的 BGM0504 三期临床试验结果显示显著的体重减轻和多项代谢参数的改善，包括平均体重减少 19.3% 和收缩压降低 22.9 mmHg。该药物的疗效超越了体重管理，表明 GIP 的角色从辅助因素转变为代谢调节中的关键变量。这种综合方法突显了 BGM0504 同时应对多种慢性疾病的潜力，标志着减肥药市场的重大进展</p>

<p>, /PRNewswire/ -- As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 随着减肥药市场竞争的逐渐加剧，博瑞医药（688166.SH）最新披露的 BGM0504 三期临床数据重新点燃了市场的关注。</p>
</div><p>Mean weight reduction of 19.3%, waist circumference decrease of 16.5 cm, systolic blood pressure reduction of 22.9 mmHg in the hypertensive population, alongside uric acid reduction of 70.7 μmol/L, triglyceride reduction of 33.6%, bone mineral density showing improvement rather than decline despite weight loss, and a discontinuation rate of 0.7% in the high-dose group. If these metrics appeared individually, their significance would primarily reflect efficacy enhancement; however, when multiple parameters are simultaneously achieved in a single product, such therapies extend from singular weight management toward comprehensive metabolic management.</p>
<div class="lb-trans"><p>在高血压人群中，平均体重减少 19.3%，腰围减少 16.5 厘米，收缩压降低 22.9 mmHg，尿酸降低 70.7 μmol/L，甘油三酯降低 33.6%，尽管体重下降，骨密度却显示出改善而非下降，高剂量组的停药率为 0.7%。如果这些指标单独出现，其重要性主要反映在疗效提升上；然而，当多个参数在单一产品中同时实现时，这类疗法的作用从单一的体重管理扩展到全面的代谢管理。</p>
</div><p>Against this backdrop, a target previously regarded largely as a supporting player is now entering the core spotlight: GIP.</p>
<div class="lb-trans"><p>在这种背景下，之前被视为辅助角色的目标现在进入了核心聚光灯：GIP。</p>
</div><p>Over the past decade-plus, GLP-1 has defined the business model for weight loss drugs—high-value innovative therapeutics driven by weight reduction as the core endpoint. As the dual-agonist era advances, the role of GIP is undergoing transformation, evolving from its early perception as primarily contributing to tolerability modulation toward becoming a critical variable in metabolic architecture regulation. The significance of this shift lies not merely in adding another target, but in the broader metabolic effects associated with GIP activation.</p>
<div class="lb-trans"><p>在过去十多年中，GLP-1 定义了减肥药的商业模式——以体重减少为核心终点的高价值创新疗法。随着双激动剂时代的推进，GIP 的角色正在发生转变，从最初主要贡献于耐受性调节的认知，演变为代谢结构调节中的关键变量。这一转变的重要性不仅在于增加了另一个靶点，更在于与 GIP 激活相关的更广泛的代谢效应。</p>
</div><p><strong>From a Single Endpoint to Multi-Parameter Synergy</strong></p>
<div class="lb-trans"><p><strong>从单一终点到多参数协同</strong></p>
</div><p>From an innovation trajectory standpoint, the weight-management space has already undergone a clear upgrade cycle.</p>
<div class="lb-trans"><p>从创新轨迹的角度来看，体重管理领域已经经历了明显的升级周期。</p>
</div><p>Single-target GLP-1 drugs, with its core value primarily reflected in weight loss and glycemic control, while effects on blood pressure, lipids, and other parameters have largely been secondary, accompanying improvements. Subsequently, dual agonists pushed weight loss magnitude closer to the ~20% range and extended benefits across certain metabolic markers, but overall market pricing has still been anchored to weight reduction and glucose lowering as the primary endpoints.</p>
<div class="lb-trans"><p>单靶点的 GLP-1 药物，其核心价值主要体现在体重减轻和血糖控制上，而对血压、脂质和其他参数的影响大多是次要的、伴随的改善。随后，双激动剂将体重减轻幅度推向接近 20% 的范围，并在某些代谢标志物上扩展了益处，但整体市场定价仍然以体重减少和降低血糖作为主要终点。</p>
</div><p>Against this backdrop, BGM0504's distinguishing feature is not a breakthrough in any single metric, but rather the coordinated improvement across multiple endpoints.</p>
<div class="lb-trans"><p>在这种背景下，BGM0504 的独特之处并不是在任何单一指标上的突破，而是多个终点的协调改善。</p>
</div><p>A 16.5 cm reduction in waist circumference suggests a direct impact on visceral fat—a core risk driver—rather than an effect limited to body weight alone. A blood pressure reduction of more than 20 mmHg, together with a target achievement rate above 90%, moves the effect from &#34;ancillary improvement&#34; into a clinically actionable range. A 70.7 μmol/L decrease in uric acid and a triglyceride reduction of more than 30% are approaching the magnitude typically seen with dedicated metabolic therapies.</p>
<div class="lb-trans"><p>腰围减少 16.5 厘米表明对内脏脂肪的直接影响——这是核心风险驱动因素——而不是仅限于体重的影响。收缩压降低超过 20 mmHg，且目标达成率超过 90%，使得效果从 “附带改善” 转变为临床可操作的范围。尿酸降低 70.7 μmol/L 和甘油三酯降低超过 30% 接近专门代谢疗法通常见到的幅度。</p>
</div><p>More importantly, in the context of nearly 20% weight loss, bone mineral density did not decline but instead increased, while the discontinuation rate remained at a low 0.7%. This indicates that improved efficacy was not achieved at the expense of bone loss or reduced treatment adherence.</p>
<div class="lb-trans"><p>更重要的是，在接近 20% 的体重减轻背景下，骨密度没有下降而是增加，同时停药率保持在低水平的 0.7%。这表明，改善的疗效并不是以骨质流失或治疗依从性降低为代价实现的。</p>
</div><p>When a single drug can simultaneously improve body weight, blood pressure, blood lipids and uric acid, it demonstrates effects across multiple chronic disease populations.</p>
<div class="lb-trans"><p>当一款药物能够同时改善体重、血压、血脂和尿酸时，它在多个慢性病人群中展现了效果。</p>
</div><p><strong>From Mechanism to Differentiation: The Emerging Role of GIP</strong></p>
<div class="lb-trans"><p><strong>从机制到差异化：GIP 的崭露头角</strong></p>
</div><p>If the Phase III clinical data of BGM0504 represent the outcomes, the mechanism determines whether these outcomes are explainable and sustainable.</p>
<div class="lb-trans"><p>如果 BGM0504 的三期临床数据代表了结果，那么机制决定了这些结果是否可以解释和持续。</p>
</div><p>Within the GLP–1 pathway, weight loss primarily stems from intake control, achieved via appetite suppression and delayed gastric emptying. Improvements in blood pressure, lipid profile, and other markers are largely secondary consequences of weight reduction.</p>
<div class="lb-trans"><p>在 GLP-1 通路中，体重减轻主要源于摄入控制，通过抑制食欲和延迟胃排空来实现。血压、脂质谱和其他标志物的改善在很大程度上是体重减少的次要结果。</p>
</div><p>In contrast, GIP acts more as an intrinsic regulatory variable within the metabolic system. The GIP receptor is highly expressed in adipose tissue. Upon activation, it modulates adipose tissue blood flow and inflammatory status, thereby regulating fat distribution. This process not only affects body fat percentage but also drives coordinated improvements across multiple parameters—including blood lipids and blood pressure—by enhancing insulin sensitivity.</p>
<div class="lb-trans"><p>相比之下，GIP 更像是代谢系统内的内在调节变量。GIP 受体在脂肪组织中高度表达。激活后，它调节脂肪组织的血流和炎症状态，从而调节脂肪分布。这个过程不仅影响体脂百分比，还通过增强胰岛素敏感性推动多个参数的协调改善，包括血脂和血压。</p>
</div><p>From the Phase III data of BGM0504, a clear correlation can be observed with this mechanistic pathway. A 16.5 cm reduction in waist circumference indicates an impact on visceral fat, a key cardiometabolic risk factor. A 33.6% decrease in triglycerides, along with reduced LDL–C and elevated HDL–C, demonstrates favorable remodeling of lipid metabolism. A 70.7 μmol/L reduction in uric acid can be regarded as a coordinated outcome of an optimized metabolic milieu.</p>
<div class="lb-trans"><p>从 BGM0504 的三期数据中，可以清晰地观察到与这一机制通路的相关性。腰围减少 16.5 厘米表明对内脏脂肪的影响，这是一个关键的心代谢风险因素。甘油三酯减少 33.6%，伴随 LDL-C 降低和 HDL-C 升高，显示出脂质代谢的有利重塑。尿酸降低 70.7 μmol/L 可以视为优化代谢环境的协调结果。</p>
</div><p>For blood pressure, multiple factors act in concert—including reduced adipose inflammation, improved insulin resistance, and enhanced vascular endothelial function—leading to a systolic blood pressure reduction of over 22.9 mmHg and a 92.9% control rate in patients with concomitant hypertension. This profile reflects a holistic, metabolism–driven regulatory effect.</p>
<div class="lb-trans"><p>在血压方面，多种因素协同作用——包括减少脂肪炎症、改善胰岛素抵抗和增强血管内皮功能——导致收缩压降低超过 22.9 mmHg，合并高血压患者的控制率达到 92.9%。这一特征反映了整体的、代谢驱动的调节效应。</p>
</div><p>At the lipid metabolism level, GIP improves insulin sensitivity and modulates lipoprotein metabolism, thereby affecting hepatic synthesis and secretion of very-low-density lipoprotein (VLDL) while promoting triglyceride clearance in peripheral tissues. This results in a 33.6% reduction in triglycerides and optimized lipoprotein composition. Changes in uric acid metabolism largely reflect a metabolic cascade effect. In obesity and insulin resistance, renal uric acid excretion is impaired. By improving insulin sensitivity, reducing adipose inflammation, and optimizing energy metabolism, GIP helps restore uric acid excretion balance.</p>
<div class="lb-trans"><p>在脂质代谢水平上，GIP 改善胰岛素敏感性并调节脂蛋白代谢，从而影响极低密度脂蛋白（VLDL）的肝脏合成和分泌，同时促进外周组织的甘油三酯清除。这导致甘油三酯减少 33.6% 和脂蛋白组成优化。尿酸代谢的变化在很大程度上反映了代谢级联效应。在肥胖和胰岛素抵抗中，肾脏尿酸排泄受损。通过改善胰岛素敏感性、减少脂肪炎症和优化能量代谢，GIP 有助于恢复尿酸排泄的平衡。</p>
</div><p>Bone metabolism represents a distinctive feature of the GIP mechanism, supported by established human and mechanistic evidence. For instance, a study published in the <em>Journal of Clinical Endocrinology &amp; Metabolism</em> demonstrated that GIP significantly inhibits bone resorption independently of insulin. GIP receptors are expressed in osteoblasts; their activation promotes bone formation and suppresses bone resorption via regulation of the RANKL/OPG pathway, thereby contributing to bone remodeling. Moreover, GIP exerts additive effects when combined with GLP-1. Multiple reviews have identified GIP as a key regulatory hormone in the gut–bone axis, mediating both bone resorption inhibition and bone formation modulation during postprandial bone remodeling.</p>
<div class="lb-trans"><p>骨代谢是 GIP 机制的一个独特特征，得到了确凿的人类和机制证据的支持。例如，发表在《临床内分泌与代谢杂志》上的一项研究表明，GIP 显著抑制骨吸收，与胰岛素无关。GIP 受体在成骨细胞中表达；其激活通过调节 RANKL/OPG 通路促进骨形成并抑制骨吸收，从而有助于骨重塑。此外，当与 GLP-1 结合时，GIP 还会产生附加效应。多项综述已将 GIP 确定为肠 - 骨轴中的关键调节激素，介导餐后骨重塑期间的骨吸收抑制和骨形成调节。</p>
</div><p>Along the traditional single-target GLP-1 pathway, rapid weight loss is often accompanied by declines in bone mineral density, and studies show that the addition of GIP offsets this risk. Accordingly, the absence of bone mineral density loss—and even an improving trend—despite substantial weight reduction can be mechanistically explained by a combination of reduced bone resorption, enhanced bone formation, and an optimized metabolic milieu. This also provides mechanistic support for the long-term structural stability of dual-target therapies in chronic disease management.</p>
<div class="lb-trans"><p>在传统的单靶 GLP-1 通路中，快速减重通常伴随着骨矿密度的下降，研究表明，增加 GIP 可以抵消这一风险。因此，尽管体重显著减少，但骨矿密度没有下降，甚至出现改善趋势，可以通过减少骨吸收、增强骨形成和优化代谢环境的组合来机制性解释。这也为慢性疾病管理中双靶治疗的长期结构稳定性提供了机制支持。</p>
</div><p>Overall, GIP is not merely an auxiliary target that amplifies weight loss. Rather, it participates in system-level regulation across multiple dimensions, including fat distribution, metabolic cross-talk, and maintenance of tissue homeostasis. When this pathway is effectively activated, a therapy's impact is no longer confined to the single endpoint of body weight, but extends across a broader set of metabolic parameters. This shift also offers a mechanistic basis for understanding BGM0504's concurrent improvements across multiple cardiometabolic indicators.</p>
<div class="lb-trans"><p>总体而言，GIP 不仅仅是一个增强减重的辅助靶点。相反，它参与了多个维度的系统级调节，包括脂肪分布、代谢交叉对话和组织稳态的维持。当这一通路有效激活时，治疗的影响不再局限于体重这一单一终点，而是扩展到更广泛的代谢参数。这一转变也为理解 BGM0504 在多个心脏代谢指标上同时改善提供了机制基础。</p>
</div><p>BGM0504 is distinctive in that it deliberately increased the weighting of GIP at the design stage. According to a <em>Nature - Scientific Reports</em> publication, its dual-agonist activity is approximately three times that of tirzepatide. This difference is not merely a matter of &#34;stronger potency&#34;; rather, at comparable dose levels, BGM0504 appears to achieve higher GIP receptor engagement and more efficient signaling activation, materially increasing GIP's contribution to the overall pharmacology.</p>
<div class="lb-trans"><p>BGM0504 的独特之处在于它在设计阶段故意增加了 GIP 的权重。根据《自然 - 科学报告》的一项出版物，其双激动剂活性约为 tirzepatide 的三倍。这一差异不仅仅是 “更强的效力”；相反，在可比剂量水平下，BGM0504 似乎实现了更高的 GIP 受体结合和更有效的信号激活，实质性地增加了 GIP 对整体药理学的贡献。</p>
</div><p>Within this architecture, GLP-1 and GIP take on differentiated roles: GLP-1 provides the foundational effects on weight reduction and glycemic control, while GIP contributes more to fat distribution modulation, metabolic cross-talk, and tolerability optimization.</p>
<div class="lb-trans"><p>在这一架构中，GLP-1 和 GIP 承担着不同的角色：GLP-1 提供减重和血糖控制的基础效应，而 GIP 则更多地贡献于脂肪分布调节、代谢交叉对话和耐受性优化。</p>
</div><p><strong>From Product to Platform: GIP Is Poised to Drive a New Wave of Differentiation</strong></p>
<div class="lb-trans"><p><strong>从产品到平台：GIP 准备推动新一波差异化</strong></p>
</div><p>Once differentiation extends from mechanism into business model, shifts at the category level begin to emerge. Globally, the weight-management field is moving from single-target approaches toward multi-target combinations, along with expansion into multiple formulations and routes of administration. Beyond GLP-1 and GIP, oral options, amylin, muscle-preservation targets, and adipose signaling pathways are all becoming active frontiers of exploration.</p>
<div class="lb-trans"><p>一旦差异化从机制扩展到商业模式，类别层面的变化便开始显现。在全球范围内，体重管理领域正从单靶向方法转向多靶向组合，同时扩展到多种制剂和给药途径。除了 GLP-1 和 GIP，口服选择、淀粉酶、肌肉保护靶点和脂肪信号通路都成为了活跃的探索前沿。</p>
</div><p>In this landscape, BrightGene Bio-Medical's strategy is closer to a platform-based approach.</p>
<div class="lb-trans"><p>在这一背景下，博瑞医药的战略更接近于平台型方法。</p>
</div><p>Building around BGM0504, the company has not only strengthened the GIP component of its mechanism, but has also advanced multiple parallel programs and modalities, including combinations of BGM0504 with amylin, an MSTN cyclic peptide, an ALK7-targeting siRNA, and several oral formulations. The goal is to assemble a systematic set of capabilities spanning adipose tissue, muscle, bone metabolism, and diverse dosing scenarios. In other words, the thesis is no longer simply to develop a single weight-loss drug, but to build a broader metabolic regulation platform.</p>
<div class="lb-trans"><p>围绕 BGM0504，公司不仅加强了其机制中的 GIP 成分，还推进了多个平行项目和模式，包括 BGM0504 与淀粉酶、MSTN 环肽、ALK7 靶向 siRNA 以及几种口服制剂的组合。目标是组建一个涵盖脂肪组织、肌肉、骨代谢和多种给药场景的系统能力。换句话说，论点不再仅仅是开发一种减重药物，而是构建一个更广泛的代谢调节平台。</p>
</div><p>This brings us back to the original question: why was BGM0504 able to deliver consistent improvements across multiple endpoints at the same time? GIP affects multiple metabolic pathways. Clinical trials show that GLP-1/GIP dual agonists produce effects across body weight, glycemic control, blood pressure, lipid metabolism, and uric acid levels. GIP is increasingly emerging as a key variable shaping the next phase of differentiation in this space.</p>
<div class="lb-trans"><p>这让我们回到最初的问题：为什么 BGM0504 能够在多个终点上同时实现一致的改善？GIP 影响多个代谢通路。临床试验表明，GLP-1/GIP 双激动剂在体重、血糖控制、血压、脂质代谢和尿酸水平等方面产生效果。GIP 正日益成为塑造这一领域下一阶段差异化的关键变量。</p>
</div><p>SOURCE BrightGene</p>
<div class="lb-trans"><p>来源：博瑞医药</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEyJk5ld3NJdGVtSWQ9Q041NTgwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTIwMjA4UFJfTkVXU19VU1BSX19fX19DTjU1ODAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN55802&amp;Transmission_Id=202605120208PR_NEWS_USPR_____CN55802&amp;DateId=20260512"/></p>

02:08 ETGIP 从辅助角色转变为关键变量：博瑞医药的 III 期结果显示其在减重领域的差异化